Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting

Cancer Research and Treatment- South Korea

doi 10.4143/crt.2019.713

Full Text

Abstract

Available in

Date

Authors

Publisher

Korean Cancer Association

Related search

Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Efficacy of the Combination Use of Aprepitant and Palonosetron for Improving Nausea in Various Moderately Emetogenic Chemotherapy Regimens

BMC pharmacology & toxicology
MedicinePharmacology
2019English

Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy

Cancer Management and Research
Oncology
2009English

Pharmacoeconomic Analysis of Using Aprepitant Plus Standard Antiemetic Therapy for Prevention of Nausea and Vomiting Associated With Highly and Moderately Emetogenic Cancer Chemotherapy in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective

Future Oncology
MedicineCancer ResearchOncology
2019English

Incidence of Chemotherapy-Induced Nausea and Vomiting With Moderately Emetogenic Chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) Study

Supportive Care in Cancer
Oncology
2015English

Stability of Azasetron-Dexamethasone Mixture for Chemotherapy-Induced Nausea and Vomiting Administration

Oncotarget
Oncology
2017English

Real-World Effectiveness of Palonosetron-Based Antiemetic Regimens: Preventing Chemotherapy-Induced Nausea and Vomiting

Journal of Comparative Effectiveness Research
Health Policy
2019English

Palonosetron (Aloxi): A Second-Generation 5-Ht3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting

Baylor University Medical Center Proceedings
Medicine
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy